Integra LifeSciences (NASDAQ:IART) Issues Q1 Earnings Guidance

Integra LifeSciences (NASDAQ:IART) updated its first quarter earnings guidance on Tuesday. The company provided EPS guidance of $0.40 to $0.45 for the period, compared to the consensus EPS estimate of $0.54. The company issued revenue guidance of $375 million to $385 million, compared to the consensus revenue estimate of $400.11 million. Integra LifeSciences also updated its FY 2025 guidance to 2.410-2.510 EPS.

Integra LifeSciences Trading Down 2.7 %

IART opened at $21.45 on Tuesday. The company has a quick ratio of 0.73, a current ratio of 1.20 and a debt-to-equity ratio of 0.79. The stock has a market cap of $1.66 billion, a PE ratio of -236.16, a price-to-earnings-growth ratio of 0.73 and a beta of 1.17. The company has a fifty day moving average of $23.68 and a 200-day moving average of $21.81. Integra LifeSciences has a twelve month low of $16.81 and a twelve month high of $44.91.

Integra LifeSciences (NASDAQ:IART) last issued its earnings results on Tuesday, February 25th. The life sciences company reported $0.97 EPS for the quarter, beating the consensus estimate of $0.85 by $0.12. The company had revenue of $442.65 million during the quarter, compared to the consensus estimate of $445.15 million. Integra LifeSciences had a positive return on equity of 12.35% and a negative net margin of 0.42%. The firm’s revenue for the quarter was up 11.5% compared to the same quarter last year. During the same period last year, the business posted $0.89 EPS. On average, sell-side analysts predict that Integra LifeSciences will post 2.45 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the company. Citigroup boosted their price objective on Integra LifeSciences from $16.00 to $22.00 and gave the stock a “sell” rating in a report on Tuesday, November 5th. Morgan Stanley started coverage on shares of Integra LifeSciences in a research report on Monday, December 2nd. They set an “underweight” rating and a $20.00 price objective on the stock. Three investment analysts have rated the stock with a sell rating, five have given a hold rating and one has given a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $23.00.

Insider Buying and Selling at Integra LifeSciences

In other Integra LifeSciences news, EVP Michael J. Mcbreen sold 1,700 shares of the business’s stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $24.16, for a total transaction of $41,072.00. Following the transaction, the executive vice president now directly owns 56,182 shares of the company’s stock, valued at approximately $1,357,357.12. The trade was a 2.94 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 3.10% of the stock is currently owned by corporate insiders.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.